<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>109(10)</volume><submitter>Giessrigl B</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Breast cancer is the leading cause of cancer death in women living in the western hemisphere. Despite major advances in first-line endocrine therapy of advanced oestrogen receptor (ER)-positive breast cancer, the frequent recurrence of resistant cancer cells represents a serious obstacle to successful treatment. Understanding the mechanisms leading to acquired resistance, therefore, could pave the way to the development of second-line therapeutics. To this end, we generated an ER-positive breast cancer cell line (MCF-7) with resistance to the therapeutic anti-oestrogen fulvestrant (FUL) and studied the molecular changes involved in resistance.&lt;h4>Methods&lt;/h4>Naive MCF-7 cells were treated with increasing FUL concentrations and the gene expression profile of the resulting</pubmed_abstract><journal>British journal of cancer</journal><pagination>2751-62</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3833203</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.</pubmed_title><pmcid>PMC3833203</pmcid><pubmed_authors>Giessrigl B</pubmed_authors><pubmed_authors>Kalipciyan M</pubmed_authors><pubmed_authors>Jeitler M</pubmed_authors><pubmed_authors>Krieger S</pubmed_authors><pubmed_authors>Mader RM</pubmed_authors><pubmed_authors>Krupitza G</pubmed_authors><pubmed_authors>Gollinger M</pubmed_authors><pubmed_authors>Schmidt WM</pubmed_authors><pubmed_authors>Jager W</pubmed_authors><pubmed_authors>Bilban M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.</name><description>&lt;h4>Background&lt;/h4>Breast cancer is the leading cause of cancer death in women living in the western hemisphere. Despite major advances in first-line endocrine therapy of advanced oestrogen receptor (ER)-positive breast cancer, the frequent recurrence of resistant cancer cells represents a serious obstacle to successful treatment. Understanding the mechanisms leading to acquired resistance, therefore, could pave the way to the development of second-line therapeutics. To this end, we generated an ER-positive breast cancer cell line (MCF-7) with resistance to the therapeutic anti-oestrogen fulvestrant (FUL) and studied the molecular changes involved in resistance.&lt;h4>Methods&lt;/h4>Naive MCF-7 cells were treated with increasing FUL concentrations and the gene expression profile of the resulting</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Nov</publication><modification>2025-04-26T17:40:15.319Z</modification><creation>2019-03-27T03:08:51Z</creation></dates><accession>S-EPMC3833203</accession><cross_references><pubmed>24169358</pubmed><doi>10.1038/bjc.2013.583</doi></cross_references></HashMap>